
Viva BioInnovator (VBI) is the specialized investment and incubation division of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program.
VBI's unique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model.
VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy.
If you would like to learn more about us, please visit: www.vivabioinnovator.com
Or send an email to innovation@vivabiotech.com
If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
Location: China, Shanghai, Zhangjiang
Employees: 11-50
Founded date: 2014
Investment Type: Venture Capital; Accelerator
Investment Stage: Pre-Seed; Seed; Series A
Mentions in press and media 6
Date | Title | Description | Source |
23.06.2022 | Viva Biotech Successfully Held The 3rd Annual Partnership Su... | SHANGHAI, June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partn... | en.prnasia... |
10.02.2022 | New US Laboratory and funding for HAYA Therapeutics | The company will use the funding to grow its team in Switzerland and San Diego. HAYA’s main headqu... | startuptic... |
20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | Along side Broadview Ventures, HAYA Therapeutics’ seed round attracted additional investors includ... | startuptic... |
20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | Along side Broadview Ventures, HAYA Therapeutics’ seed round attracted additional investors includin... | startuptic... |
10.03.2021 | Viva Biotech Successfully Held 2021 Partnership Summit -- No... | SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2... | oaoa.com/n... |
03.12.2019 | Bright Angel Therapeutics Announces New Funding to Advance T... | TORONTO – Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal ... | lumiravent... |